ArticleGut1994
Impact of familial amyloid associated polyneuropathy on duodenal endocrine cells.
Article in Gut, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 47 citations in OpenAlex.
- Small intestinal bacterial overgrowth in variant transthyretin amyloidosis (A-ATTRv).Orphanet journal of rare diseases · 2025Observational
- Fecal calprotectin levels are elevated in transthyretin amyloidosis patients with gastrointestinal manifestations.Medicine · 2020Observational
- Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2019Review
- Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis.Neurology and therapy · 2014Article
- Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2013Article
- Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy.Neurogastroenterology and motility · 2012Article
- Systemic amyloidosis and the gastrointestinal tract.Nature reviews. Gastroenterology & hepatology · 2009Review
- Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy.Digestive diseases and sciences · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duodenal endocrine cells in 11 patients with familial amyloid associated polyneuropathy (FAP) were compared with those in 12 healthy volunteers by means of immunohistochemistry and morphometry. The total endocrine cell content, determined by the argyrophilic reaction and chromogranin A immunoreactivity, was significantly reduced in FAP patients compared with controls. There was a significant reduction in the serotonin, cholecystokinin/gastrin, and secretin immunoreactive cell content. A decreased cell content was also noted for somatostatin and gastric inhibitory polypeptide immunoreactive cells but this was not statistically significant. Amyloid deposits were noted in seven of the 11 biopsy specimens from FAP patients, but otherwise the duodenum was histologically normal in both groups. The reduction in endocrine cell content was not correlated with the degree of amyloid deposit in the duodenum. These findings indicate that patients with FAP have reduced intestinal endocrine cells. This does not seem to be related to amyloid deposits in the mucosa or to villous or crypt abnormalities. The observed changes in endocrine cells may contribute to the development of intestinal motility dysfunction and maldigestion in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.